- 394studies in the library match, of 29,780
- 94name it in the title
- 1988–2026years published
- 386peer-reviewed articles
The query: title or abstract mentions "rapidly progressive dementia/Alzheimer's/cognitive/decline", "rapid decline", "rapid progression", "rapid deterioration", "rapid progressors", "fast decliners", "Creutzfeldt" or "prion", matched case-insensitively against each record's title and abstract (its summary field) in alzhub's library of 29,780 study records, as of 2026-11-09. Every count on this page comes from that match. The matched list as JSON.
Rapidly progressive dementia is a clinical label for a decline that unfolds over weeks to a couple of years rather than many years. It prompts a search for treatable or distinct causes, including prion diseases such as Creutzfeldt-Jakob disease, autoimmune encephalitis and some infections, alongside unusually fast forms of Alzheimer's.
Within Alzheimer's itself, the papers ask what predicts a faster course: age at onset, the pattern of brain changes, genes, other illnesses and the type of symptoms at diagnosis. Trials also use the rate of decline as their main measure, so how fast decline is measured matters for how treatment effects are judged.
This page describes what published research in alzhub's library reports. It is not medical advice and does not apply to any one person: a doctor who knows the person's history is the only one who can say what a result or a treatment means for them.
What the studies report, in their own words
Whole sentences copied from the abstract or key findings of the highest-scoring matched studies, chosen because they mention the subject and give a figure. 8 of the 394 matched records are quoted; each links to its study page and from there to the paper.
“Post-hoc analyses showed that outcomes in the ENGAGE high-dose group were affected by an imbalance in a small number of patients with extremely rapid progression and by lower exposure to the target dose of 10 mg/kg.”
“Higher p-tau181 also showed a borderline statistically significant association with more rapid decline in the Symbol Digit Modalities Test.”
“Cases were segregated into earlier disease onset (25%), tremor dominant (31%), non-tremor dominant (36%) and rapid disease progression without dementia (8%) subgroups.”
“Results In 1993, 12.2% of those aged 70 or older had CI compared with 8.7% in 2002 (P Conclusions These findings support the hypothesis of a compression of cognitive morbidity between 1993 and 2004, with fewer older Americans reaching a threshold of significant CI and a more rapid decline to death among those who did.”
“Longitudinal analysis showed a significant rise in plasma p-tau181 values over time, especially in fast progressors.”
“During follow-up, participants with AD-like CSF signature determined by Aβ-PET-based cutoffs from Lumipulse showed rapid progression of cognitive decline in 139 subjects, after adjustment for potential confounders, compared with those with a normal CSF signature.”
“GBA mutations (β = 4.65; 95% CI, 1.72-7.58; P = .002), E326K (β = 3.42; 95% CI, 0.66-6.17; P = .02), and GBA variants combined as a single group (β = 4.01; 95% CI, 1.95-6.07; P = 1.5 × 10-4) were associated with a more rapid decline in MDS-UPDRS III score.”
“Results A total of 162 samples were analyzed, composed of 91 normal control individuals (51 male, 33 female, and 7 not recorded), 34 neurological disease control individuals (19 male and 15 female), and 37 with prion disease (22 male and 15 female).”
What kind of evidence it is
By study design
| Design (as recorded) | Studies |
|---|---|
| Systematic review or meta-analysis | 7 |
| Other clinical trial | 1 |
| Cohort or longitudinal study | 47 |
| Case-control study | 2 |
| Cross-sectional study | 5 |
| Other recorded design | 2 |
| No design recorded | 330 |
The design is the one named in alzhub's record for the study; a record with none is counted as "no design recorded".
By year
| Year | Studies | Share |
|---|---|---|
| 2026 | 18 | |
| 2025 | 39 | |
| 2024 | 12 | |
| 2023 | 12 | |
| 2022 | 19 | |
| 2021 | 16 | |
| 2020 | 18 | |
| 2019 | 26 | |
| 2018 | 23 | |
| 2017 | 17 | |
| 2016 and earlier | 194 |
Other counts within the matched set
| Peer-reviewed articles | 386 |
| Marked open access in the record | 115 |
| Rated "high" evidence strength in alzhub's summary | 13 |
| Rated "moderate" evidence strength in alzhub's summary | 75 |
| Rated "low" evidence strength in alzhub's summary | 303 |
| No evidence-strength rating | 3 |
| Records stating a participant count | 118 |
| Median participants (those records) | 108 |
| Largest participant count | 121,623 |
Within the 394 matched studies
| Studies… | Count | Rule |
|---|---|---|
| …that mention Creutzfeldt-Jakob or prion disease | 273 | the abstract also contains "Creutzfeldt" or "prion" |
| …that mention a predictor of faster decline | 56 | the abstract also contains "predict" |
| …that also mention APOE | 35 | the abstract also contains "APOE" or "apolipoprotein E" |
The 10 highest-scoring matched studies
Title matches first, then by alzhub's usefulness score, which rates a study's design, journal, evidence and recency, not whether its result is good news.
- Diagnosing Sporadic Creutzfeldt-Jakob Disease by the Detection of Abnormal Prion Protein in Patient Urine
- Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt-Jakob disease: results from the Swedish Mortality Registry
- Performance of Alzheimer Disease Plasma Biomarkers in Patients With Prion Diseases
- Rapidly progressive Alzheimer's disease features distinct structures of amyloid-β
- Risk factors for Creutzfeldt-Jakob disease: a reanalysis of case-control studies
- Transcriptomic predictors of rapid progression from mild cognitive impairment to Alzheimer's disease
- A novel prion disease associated with diarrhea and autonomic neuropathy
- Prion-like spreading of pathological α-synuclein in brain
- R47H TREM2 variant increases risk of typical early-onset Alzheimer's disease but not of prion or frontotemporal dementia
- Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease
Systematic reviews and meta-analyses in the set
7 of the matched records are recorded as a systematic review, meta-analysis or umbrella review; the highest-scoring not already listed above:
- Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials
- Neurofilament Light Chain in Cerebrospinal Fluid and Blood as a Biomarker for Neurodegenerative Diseases: A Systematic Review and Meta-Analysis
- Neuropathology underlying clinical variability in patients with synucleinopathies
- A clinico-pathological study of subtypes in Parkinson's disease
- Orthostatic hypotension and REM sleep behaviour disorder: impact on clinical outcomes in α-synucleinopathies
Newest matched studies
- Reduced phosphatases and hyperphosphorylated glutamatergic receptors persist from early to late stages of prion disease
- Repetitive RNA Is Present in Prion-Infected Mouse Brains
- APOE ε4 Carrier Status and Cognitive Decline in Mild-to-Moderate Alzheimer’s Disease: A Linear Mixed-Effects Analysis of the Placebo Arm of EXPEDITION 1
- Prion disease mimicking rapidly progressive Alzheimer disease: case series and systematic review
- A New Frontier in CWD Detection: Antemortem Plasma Biomarkers and Behavioral Profiling in Transgenic Mouse Models
Journals with the most matched studies
| Journal | Studies |
|---|---|
| Neurology | 23 |
| Acta neuropathologica | 14 |
| Alzheimer's & dementia : the journal of the Alzheimer's Association | 14 |
| Brain : a journal of neurology | 13 |
| Journal of Alzheimer's disease : JAD | 13 |
Questions
- What counts as rapidly progressive dementia?
- Clinicians use the term for a decline from normal to dementia over months, or within about two years, rather than the many years typical of Alzheimer's. It calls for tests to rule out prion disease, autoimmune and infectious causes, some of which are treatable.
- How many studies on rapid progression in dementia does alzhub hold?
- 394 of the 29,780 study records in alzhub's library match the query "title or abstract mentions "rapidly progressive dementia/Alzheimer's/cognitive/decline", "rapid decline", "rapid progression", "rapid deterioration", "rapid progressors", "fast decliners", "Creutzfeldt" or "prion""; 94 of them name it in the title. Counted from the records when this page was built.
- What kinds of study are they?
- 7 systematic review or meta-analysis, 1 other clinical trial, 47 cohort or longitudinal studys, 2 case-control studys, 5 cross-sectional studys; 330 record no design.
- What is the most recent study in the set?
- "Reduced phosphatases and hyperphosphorylated glutamatergic receptors persist from early to late stages of prion disease" (bioRxiv, 2026), the newest by publication date among the matched records.
- Which journals publish most on it?
- Neurology (23); Acta neuropathologica (14); Alzheimer's & dementia : the journal of the Alzheimer's Association (14), counted across the matched records.
Read on
- Early, middle and late stagesWhat changes at each stage, in plain language.
- Life expectancy after diagnosisThe survival studies.
- Getting a diagnosisWhat the diagnostic process involves.